CMPS vs NVCT: fair value comparison
COMPASS Pathways plc and Nuvectis Pharma, Inc. · Updated 2026-10-19
CMPS has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. NVCT has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, CMPS currently ranks higher by quality score.
| CMPS | NVCT | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $10.75 | $18.60 |
| 12-month range | $4.94–$15.19 | $5.65–$28.53 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #300 of 301 Healthcare | #301 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Moderate | — |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The upper-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: CMPS fair value analysis · NVCT fair value analysis